Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 50 years of age
Patients with age-related macular degeneration (AMD)
Best corrected visual acuity (BCVA) of 20/40 to 20/400 (Snellen equivalent, on ETDRA charts) inclusive
Evidence of leakage due to choroidal neovascularization (CNV)
You may not be if
Choroidal neovascularization (CNV) in either eye due to causes other than age related macular degeneration, such as ocular histoplasmosis, trauma, or pathologic myopia
Known hypersensitivity to ranibizumab, fluorescein, indocyanin green (ICG) or any of the ingredients of the formulation used, or any of the medications used
Any other restriction according to the use of ranibizumab
Active intraocular inflammation (grade trace or above) in the study eye
Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
Clareo Health | A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
